Contact Us
Drug Search Results
More Filters [+]

LY-3000328

Alternative Names: ly-3000328, ly3000328, ly 3000328
Latest Update: 2022-01-01
Latest Update Note: PubMed Publication

Product Description

Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25313327/)

Mechanisms of Action: CTSS Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LY-3000328

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
I5U-MC-ANBB

P1

Completed

Healthy Volunteers

2012-05-01

Recent News Events

Date

Type

Title

01/01/2022

PubMed

 Cathepsin S is a novel target for age-related dry eye.

09/19/2021

PubMed

 Cathepsin S Evokes PAR2-Dependent Pain in Oral Squamous Cell Carcinoma Patients and Preclinical Mouse Models.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions